Chinese maker of chromatography and filtration consumables used to purify biopharmaceutical drugs.
Chinese maker of chromatography and filtration consumables used to purify biopharmaceutical drugs.
Sells the resin beads and filled columns that separate a drug from impurities, and these are used up batch after batch. Once a customer's purification step is approved, replacement orders repeat. It competes against imported media from large foreign suppliers as Chinese drugmakers look for local sources.
In one line: A Chinese Cytiva/Repligen for bioprocess purification consumables.
Moat: narrow (switching costs, process know-how). Validated purification consumables are costly for a drugmaker to swap mid-process.
Headquarters: Suzhou, Jiangsu, China · Employees: 417
Size Suzhou Sepax Technologies (688758.SS) is a China Health Care company (Medical Specialties) with a market value of $1.31B, the 1721st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥21.26 on 18 Nov 2026.
Performance Over six months the shares gained 8.1%, against -13.3% for the median peer and -20.0% for the China market (cap-weighted) — 4th highest of 21 in its peer set.
Growth Revenue grew 27.6% over the last twelve months (peer median +7.3%); the operating margin is 39.5% (peer median 6.7%).
Valuation It trades at 46.0× forward earnings against a peer median of 22.9× (3rd most expensive of 17).
Price implies For today's price to make sense, revenue must grow about 23% a year for seven years (Req g). Recent delivered growth is +24%, so the hurdle is -1 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 12.5 points above its cost of capital (8.0% WACC).
Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥525M | CN¥400M | CN¥314M | CN¥244M | CN¥212M |
| Revenue growth | — | +28% | +28% | +15% | — |
| Gross profit | CN¥390M | CN¥270M | CN¥210M | CN¥162M | CN¥153M |
| EBITDA | n/a | CN¥144M | CN¥102M | CN¥64.8M | CN¥56.1M |
| Net income | CN¥198M | CN¥127M | CN¥85.2M | CN¥52.5M | CN¥47.1M |
| Free cash flow | CN¥109M | CN¥116M | CN¥55.6M | CN¥27.0M | -CN¥13.6M |
| Capital expenditure | CN¥78.8M | CN¥14.0M | CN¥13.5M | CN¥19.1M | CN¥48.7M |
| Total debt | CN¥171M | CN¥55.6M | CN¥43.9M | CN¥49.0M | CN¥51.5M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Suzhou Sepax Technologies 688758.SS | $1.31B | +8% | +28% | 40% | 46.0× | 22.8% |
| Danaher DHR | $161B | +34% | +6% | 21% | 25.1× | 20.8% |
| Repligen RGEN | $11.0B | +55% | +14% | 9% | 71.0× | 56.9% |
| Sartorius SRT.DE | $19.9B | +26% | +4% | 18% | 43.0× | 25.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688758.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -14.6% | -0.9% | 3rd lowest of 21 |
| 6-month return | +8.1% | -13.3% | 4th highest of 21 |
| Distance from 52-week high | -38.9% | -32.6% | 8th lowest of 21 |
| Revenue growth (TTM) | +27.6% | +7.3% | 3rd highest of 20 |
| Operating margin | 39.5% | 6.7% | 2nd highest of 20 |
| Forward P/E | 46.0× | 22.9× | 3rd most expensive of 17 |
| Growth the price implies (Req g, 7 yrs) | 22.8% | 10.3% | 3rd most demanding of 14 |
| Growth delivered (Del g) | +23.6% | +9.9% | 3rd highest of 14 |
| Hurdle (Req g minus delivered) | -0.8 pp | -6.9 pp | 6th most demanding of 14 |
| ROIC minus cost of capital | +12.5 pp | +0.2 pp | 2nd highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Suzhou Sepax Technologies 688758.SS | China | $1.31B | +8% | +28% | 40% | 46.0× | 22.8% | +23.6% |
| Beijing Balance Medical Technology 688198.SS | China | $1.31B | -32% | +10% | 28% | 41.5× | 20.7% | +27.6% |
| Sonoscape Medical 300633.SZ | China | $1.31B | -10% | +18% | 4% | 34.7× | n/a | n/a |
| Ovctek China 300595.SZ | China | $1.33B | -25% | 0% | 28% | 19.4× | 8.3% | +16.5% |
| STAAR Surgical STAA | United States | $1.27B | -23% | +42% | 7% | 46.9× | 35.1% | +7.9% |
| NovoCure NVCR | United States | $1.25B | -40% | +13% | -17% | n/a | n/a | n/a |
| Sansure Biotech 688289.SS | China | $1.24B | -17% | -1% | 1% | 35.6× | n/a | n/a |
| Eyebright Medical Technology (Beijing) 688050.SS | China | $1.21B | -16% | +21% | 16% | 23.9× | 10.3% | +40.3% |
| Shenzhen Edge Medical 2675.HK | Hong Kong | $1.21B | -51% | +132% | 2% | 120.2× | n/a | n/a |
| CONMED CNMD | United States | $1.43B | +30% | +2% | 2% | 10.4× | 31.6% | +9.8% |
| Tandem Diabetes Care TNDM | United States | $1.19B | +13% | +7% | -2% | n/a | n/a | n/a |
| PROCEPT BioRobotics PRCT | United States | $1.45B | -10% | +17% | -34% | n/a | n/a | n/a |
| Sinocare 300298.SZ | China | $1.45B | +4% | +7% | 6% | 21.5× | 9.5% | +18.3% |
| Inner Mongolia Furui Medical Science 300049.SZ | China | $1.45B | -31% | +11% | 25% | 41.9× | 2.9% | +14.6% |
| El.En ELN.MI | Italy | $1.46B | +11% | +3% | 15% | 22.0× | 10.7% | +7.7% |
| Shandong Weigao Orthopaedic Device 688161.SS | China | $1.14B | -29% | -6% | 18% | 24.9× | 11.3% | -3.5% |
| Beijing Strong Biotechnologies 300406.SZ | China | $1.13B | -4% | -4% | 36% | 18.2× | 1.7% | +9.9% |
| Alpha Tau Medical DRTS | United States | $1.11B | +7% | n/a | n/a | n/a | n/a | n/a |
| Shanghai MicroPort Endovascular MedTech 688016.SS | China | $1.55B | -19% | +16% | 44% | 16.4× | 2.7% | +23.4% |
| Nihon Kohden 6849.T | Japan | $1.55B | +3% | 0% | 7% | 18.8× | -3.5% | +3.3% |
| Enovis ENOV | United States | $1.56B | +2% | +3% | 4% | 7.6× | 20.0% | -6.0% |